- Latest available (Revised)
- Point in Time (01/06/2005)
- Original (As adopted by EU)
After exit day there will be three versions of this legislation to consult for different purposes. The legislation.gov.uk version is the version that applies in the UK. The EU Version currently on EUR-lex is the version that currently applies in the EU i.e you may need this if you operate a business in the EU.
The web archive version is the official version of this legislation item as it stood on exit day before being published to legislation.gov.uk and any subsequent UK changes and effects applied. The web archive also captured associated case law and other language formats from EUR-Lex.
Version Superseded: 01/08/2011
EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.
Adverse reproductive effects are of two main types:
impairment of male or female fertility, and
impacts on the normal development of progeny (developmental toxicity).
Possible effects on all aspects of reproductive physiology in both males and females, as well as possible effects on pre-natal and post-natal development, must be investigated and reported. If in exceptional circumstances, it is claimed that such testing is unnecessary, that claim must be fully justified.
While the standard reference point for treatment responses are concurrent control data, historical control data may be helpful in the interpretation of particular reproductive studies. Where submitted, historical control data should be from the same species and strain, maintained under similar conditions and should be from contemporaneous studies. The information on historical control data provided must include:
identification of species and strain, name of the supplier, and specific colony identification, if the supplier has more than one geographical location,
name of the laboratory and the dates when the study was performed,
description of the general conditions under which animals were maintained, including the type or brand of diet and, where possible, the amount consumed,
approximate age, in days, of the control animals at the beginning of the study and at the time of killing or death,
description of the control group mortality pattern observed during or at the end of the study, and other pertinent observations (e.g. diseases, infections), and
name of the laboratory and the examining scientist responsible for gathering and interpreting the toxicological data from the study.
The studies reported, taken together with other relevant data and information on the active substance, must be sufficient to permit the identification of effects for reproduction, following repeated exposure to the active substance, and in particular must be sufficient:
to identify direct and indirect effects on reproduction resulting from exposure to the active substance,
to identify any enhancement of general toxic effects (noted during short-term and chronic toxicity testing),
to establish the dose-response relationship, to identify changes in toxic signs and manifestations observed, and
to establish the Noael.
A reproduction toxicity study in rats over at least two generations must always be reported.
The tests must be carried out in accordance with Directive 87/302/EEC, Part B, two-generation reproduction toxicity test. In addition organ weight of reproductive organs must be reported.
Where necessary for a better interpretation of the effects on reproduction and as far as this information is not yet available it could be necessary to perform supplementary studies in order to provide the following information:
separate male and female studies,
three segment designs,
dominant lethal assay for male fertility,
cross-matings of treated males with untreated females and vice versa,
effects on spermatogenesis,
effects on oogenesis,
sperm motility, mobility and morphology, and
investigation of hormonal activity.
The studies reported, taken together with other relevant data and information on the active substance, must be sufficient to permit effects on embryonic and foetal development, following repeated exposure to the active substance, to be assessed, and in particular must be sufficient:
to identify direct and indirect effects on embryonic and foetal development resulting from exposure to the active substance,
to identify any maternal toxicity,
to establish the relationship between observed responses and dose in both dam and offspring,
to identify changes in toxic signs and manifestations observed, and
to establish the Noael.
Furthermore, the tests will give additional information on any enhancement of general toxic effects of pregnant animals.
The tests must always be carried out.
Developmental toxicity must be determined both to rat and rabbit by the oral route. Malformations and variations should be reported separately. A glossary of terminology and diagnostic principles for malformations and variations must be given in the report.
The tests must be carried out in accordance with Directive 87/302/EEC, Part B, teratogenicity test — rodent and non-rodent.]
Textual Amendments
Substance within the meaning of the definition of Article 2, point 3.
The Whole Directive you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: